Laboratorios Farmaceuticos Rovi, S.A./ADR

Drug Name	Phase	Indication	Designations	Patent
Lactase	Phase 3	Hypolactasia	-	-
Depigoid Parietaria judaica 1000DPP/ml	Phase 3	Allergic Rhinoconjunctivitis	-	-
Glucosamine and chondroitin sulfate combination (Eurofarma)	Phase 3	Osteoarthritis of Knee	-	-
Minoxidil Topical Foam	Phase 3	Alopecia	-	-
Study group - quadrivalent recombinant hemagglutinin influenza vaccine	Phase 3	Influenza, Human	-	-
Rizatriptan 10 mg + Naproxen 550mg	Phase 3	Migraine	-	-
Alenia® 12mcg + 400mcg / Alenia® 6mcg + 200mcg	Phase 3	Asthma Copd	-	-
Nimotuzumab	Phase 3	Esophageal Cancer	-	-
Filgrastim (Eurofarma)	Phase 3	Neutropenia in Breast Cancer	-	-
DMMET-01	Phase 3	Diabetes Type 2	-	-
Dexketoprofen/Vitamin B	Phase 3	Acute Low Back Pain	-	-
Chlorthalidone 25 mg + amiloride hydrochloride 5 mg	Phase 3	Arterial Hypertension	-	-
Foraseq	Phase 3	ASTHMA	-	-
FDC of codeine 30 mg/dipyrone 500 mg	Phase 3	Pain	-	-
Immunotherapy with modified extract of O. europaea pollen	Phase 3	Allergy	-	-
Etoricoxib + Cyanocobalamin fixed dose	Phase 3	Acute Low-back Pain	-	-
Desloratadine / Betamethasone in fixed dose	Phase 3	Allergic Rhinitis	-	-
Mometasone furoate	Phase 3	Mild to Moderate Persistent Allergic Rhinitis	-	-
Noex	Phase 3	Allergic Rhinitis	-	-
Metformin hydrochloride	Phase 3	Type 2 Diabetes	-	-
Desloratadine , Prednisolone	Phase 3	Allergic Rhinitis	-	-
Fixed Dose Etoricoxib + Betamethasone	Phase 3	Bursitis	-	-
Etoricoxib 90 mg + diacerein 50 mg	Phase 3	Pain Management	-	-
Treatment with nifedipine	Phase 3	High Blood Pressure (& [Essential Hypertension])	-	-
Losartan/Chlorthalidone in fixed dose	Phase 3	Essential Arterial Hypertension	-	-
Etoricoxib + Tizanidine fixed dose	Phase 3	Acute Low-back Pain	-	-
Levetiracetam	Phase 3	Epilepsy	-	-
Candicort®	Phase 3	Tinea	-	-
Glucosamine sulphate and chondroitin sulphate association	Phase 3	Osteoarthritis of the Knee	-	-
Group 1	Phase 3	Nasal Congestion and Inflammations	-	-
Sodium picosulphate, light magnesium oxide and anhydride citric acid.	Phase 3	Subjects Undergoing a Complete Exploratory Diagnostic Colonoscopy for the First Time.	-	-
Immunotherapy with modified extract of Olea europaea pollen	Phase 3	Rhinitis or Rhinoconjunctivitis With or Without Asthma Induced by Hypersensitivity to Olea Europea Pollen	-	-
glucosamine sulfate /chondroitin sulfate - capsules	Phase 3	Knee Osteoarthritis	-	-
Lactase Oral Tablets	Phase 3	Lactose Intolerance	-	-
Liquaemin	Phase 3	Hemodialysis Complication	-	-
application of the topic gel	Phase 3	Acne Vulgaris	-	-
Dextralgen	Phase 3	Lumbar Sciatic Pain	-	-
Etoricoxib + Betamethasone fixed dose	Phase 3	Gout Arthritis	-	-
Inj. Goserelin (Test) Subcutaneously	Phase 3	Advanced Prostate Cancer	-	-
brompheniramine + phenylephrine	Phase 3	Nasal Congestion and Inflammations	-	-
Eszopiclone	Phase 3	INSOMNIA	-	-
Ibuprofen + Loratadine fixed dose	Phase 3	Common Cold	-	-
Meloxicam	Phase 3	Dysmenorrhea	-	-
Experimental drug (paracetamol 500mg / fexofenadine 60mg / phenylephrine 20mg)	Phase 3	Cold	-	-
Metformin Glycinate	Phase 3	Severe Acute Respiratory Syndrome Coronavirus 2	-	-
Allergen extract (Phleum pratense)	Phase 3	Seasonal Allergic Rhinitis	-	-
Four different concentrations of Dactylis glomerata allergen extract, positive control and negative control	Phase 2	Allergy to Grass Pollen (Dactylis Glomerata)	-	-
DP/MG/14-1	Phase 2	Rhinitis	-	-
Prick test Dermatophagoides pteronyssinus allergen extract	Phase 2	Allergy Dermatophagoides Pteronyssinus	-	-
1 (Dose Response Skin Prick Tests)	Phase 2	Cat Allergy (Disorder)	-	-
Four different concentrations of Blomia tropicalis allergen extract, positive control and negative control	Phase 2	Allergy to Mites	-	-
Depigoid 50% Grasses/50% Olea europaea (2000DPP/ml)	Phase 2	Allergy	-	-
Grass pollen allergenic extract (L. perenne-C. dactylon )	Phase 2	Allergic Rhinoconjunctivitis	-	-
Lolium allergen extract	Phase 2	Allergy to Grass Pollen	-	-
Cupressus arizonica	Phase 2	Allergy to Tree Pollen	-	-
Four different concentrations of Secale cereale allergen extract, positive control and negative control	Phase 2	Allergy to Grass Pollen (Secale Cereale)	-	-
COVID-19 vaccine HIPRA 10	Phase 2	Covid19	-	-
Four different concentrations of Poa pratensis allergen extract, positive control and negative control	Phase 2	Allergy to Grass Pollen	-	-
Prick test Chenopodium album allergen extract	Phase 2	Allergy to Chenopodium Album	-	-
four differente concentrations of Alternaria alternata allergen extract, positive control and negative control	Phase 2	Allergy to Alternaria Fungus	-	-
Immunotherapy with modified extract of P. pratense pollen	Phase 2	Rhinitis, Allergic, Seasonal	-	-
Evogliptin	Phase 2	Diabetes Mellitus, Type 2	-	-
AS012	Phase 2	Non-segmental Vitiligo	-	-
Prick test Platanus acerifolia allergen extract	Phase 2	Allergy to Platanus Acerifolia	-	-
Artemisia vulgaris	Phase 2	Allergy to Pollen	-	-

📑

Catalyst DossierPRO

The full research note — thesis, the if-approved scenario, financials & smart money. Compiled by CeliA.

→

Catalyst Verdict

Full breakdown — the signals behind the verdict

Market-Implied Move

Regulatory Approvals

Frequently asked questions

What is in Laboratorios Farmaceuticos Rovi, S.A./ADR's drug pipeline?→

CatalystAlert tracks 65 drug candidates in Laboratorios Farmaceuticos Rovi, S.A./ADR's (LRVIY) pipeline across Phase 3, Phase 2. Its lead program is Lactase (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.

When is Laboratorios Farmaceuticos Rovi, S.A./ADR's next FDA catalyst?→

Laboratorios Farmaceuticos Rovi, S.A./ADR's (LRVIY) next tracked catalyst is a Phase 3 expected December 31, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.

How do I track LRVIY biotech catalysts?→

Add LRVIY to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Laboratorios Farmaceuticos Rovi, S.A./ADR's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply

Laboratorios Farmaceuticos Rovi, S.A./ADR

Market Overview

LRVIY News

Catalyst Timeline

Pipeline & FDA Submissions

AI Predictions & Institutional Flow

Market Intelligence

Regulatory Approvals

Frequently asked questions